Brief: Imunon Announces First Patient Dosed In Phase 3 Ovation 3 Study Of Imnn-001 In Newly Diagnosed Advanced Ovarian Cancer
30/07/2025 14:01
July 30 (Reuters) - Imunon Inc IMNN.O: IMUNON ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 OVATION 3 STUDY OF IMNN-001 IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER Source text: ID:nGNX9MZhHS Further company coverage: IMNN.O ((Reuters.Briefs@thomsonreuters.com;))